B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

55.02 +2.29 (+4.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,031,635
Open 52.61
Bid (Size) 54.20 (1)
Ask (Size) 59.00 (1)
Prev. Close 52.73
Today's Range 51.49 - 55.43
52wk Range 33.32 - 70.00
Shares Outstanding 110,575,547
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
+9.43%
+9.43%
1 Month
+9.43%
+9.43%
3 Month
-7.14%
-7.14%
6 Month
-4.94%
-4.94%
1 Year
+34.29%
+34.29%

More News

Read More
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Via Benzinga
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
Via Benzinga
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease
Via Benzinga
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Via Benzinga
5 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Yelp, Twilio, Atlassian, And Other Big Losers From Friday
Via Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.